Abstract
Background In response to the global pandemic of COVID-19, countries around the world began imposing stay-at-home orders, restrictions on transport, and closures of businesses in early 2020. South Africa implemented a strict lockdown in March 2020 before its first COVID-19 wave started, gradually lifted restrictions between May and September 2020, and then re-imposed restrictions in December 2020 in response to its second wave. There is concern that COVID-19-related morbidity and mortality, fear of transmission, and government responses may have led to a reduction in antiretroviral treatment (ART) initiations for HIV-infected individuals in countries like South Africa.
Methods We analyzed national, public sector, facility-level data from South Africa’s District Health Information System (DHIS) from January 2019 to March 2021 to quantify changes in ART initiation rates stratified by province, setting, facility size and type and compared the timing of these changes to COVID-19 case numbers and government lockdown levels. We excluded facilities with missing data, mobile clinics, and correctional facilities. We estimated the total number of ART initiations per study month for each stratum and compared monthly totals, by year.
Results At the 2471 facilities in the final data set (59% of all ART sites in the DHIS), 28% fewer initiations occurred in 2020 than in 2019. Numbers of ART initiations declined sharply in all provinces in April-June 2020, compared to the same months in 2019, and remained low for the rest of 2020, with some recovery between COVID-19 waves in October 2020 and possible improvement beginning in March 2021. Percentage reductions were largest in district hospitals, larger facilities, and urban areas. After the initial decline in April-June 2020, most provinces experienced a clear inverse relationship between COVID-19 cases and ART initiations but little relationship between ART initiations and lockdown level.
Conclusions The COVID-19 pandemic and responses to it resulted in substantial declines in the number of HIV-infected individuals starting treatment in South Africa, with no recovery of numbers during 2020. These delays may lead to worse treatment outcomes for those with HIV and potentially higher HIV transmission. Exceptional effort will be needed to sustain gains in combating HIV.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding for this study was provided by PEPFAR and the U.S. Agency for International Development through the EQUIP Cooperative Agreement AID-OAA-A-15-00070 to Right to Care. LL was supported by the National Institute of Mental Health of the National Institutes of Health under grant number K01MH119923. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Only aggregate data were used for this study. There were no human subjects data used and thus no IRB review for this study. There was no ethics board for collection of the original data because the data were collected in aggregate form by the government agency that owns them (National Department of Health) from its own facilities. We received permission to post our analysis of the DHIS data set from the South African National Department of Health on February 24, 2021. Permission was provided by Mbulelo Cabuko, Director: National Health Information System, Cluster: Health Information, Research, Monitoring & Evaluation, National Department of Health. Access to the data was provided through a signed Data Users' Agreement between the Clinton Health Access Initiative (CHAI, co-author JM Tucker) and the National Department of Health, signed on June 1, 2020. Documentation of these agreements can be provided if needed.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data used in this analysis are from the South African District Health Information System (DHIS II) and are owned by the South African National Department of Health. These data cannot be made publicly available by the authors. DHIS data access can be requested from the Director-General of the National Department of Health in South Africa at the following address: Director: National Health Information System Cluster: Health Information, Research, Monitoring & Evaluation Civitas Building Private Bag X 828 Pretoria, 0001, South Africa Data on COVID-19 case numbers are available from https://mediahack.co.za/datastories/coronavirus/dashboard/.
